EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY 4.0

Abatacept as a Mimic of Gamma Heavy Chain Disease

David M Manthei

Clinical Chemistry · 2023

DOI: 10.1093/clinchem/hvad074 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Clinical Chemistry, 2023. Verfasst von David M Manthei. Beteiligte Einrichtung: Department of Pathology, University of Michigan, Ann Arbor, MI 48109, United States. Hauptthemen laut MEDLINE: Heavy Chain Disease, Antirheumatic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recombinant biologic therapeutics acting as interfering substances in laboratory evaluation for paraproteins have gained recognition largely due to therapeutic monoclonal antibodies (TmAbs). Incorrect results have been reported due to these IgG kappa TmABs, with potential errors including a new M-protein diagnosis to incomplete treatment response, depending on patient history, availability of ancillary information, and which assays were performed (1). Some TmAbs—such as daratumumab and elotuzumab—are used to treat the very disease (multiple myeloma) in which monitoring paraproteins is indicated, increasing the likelihood of encountering them. Moreover, intravenously administered TmAbs can be detected for weeks post-infusion. Although these TmAbs have prototypical migrations on serum protein electrophoresis (SPEP), they may comigrate with patient-specific paraproteins causing diagnostic difficulty (2). While some techniques (e.g., mass spectrometry) may be able to identify these typical TmAb signatures with better precision, few laboratories perform such testing. Other TmAbs (e.g., infliximab, vedolizumab, rituximab) less frequently cause diagnostic difficulty because concentrations needed for detection only persist briefly post-infusion (3). Additionally, serum immunofixation (SIFE) has higher sensitivity identifying these and other small paraproteins compared to SPEP alone. In contrast to typical paraproteins, SIFE may also reveal a restricted heavy chain that lacks a corresponding light chain. This could be due to technical considerations including weak lambda staining or hidden epitopes to reagents. However, lack of light chain association could also represent heavy chain disease, where involvement of the alpha, gamma, and mu heavy chains have all been described. Gamma heavy chain disease (Franklin disease) was first reported in 1964 (4) and is often associated with B-cell neoplasms with systemic symptoms. In contrast to TmAbs, which have both light and heavy chains, therapeutic chimeric proteins have been developed joining an immunoglobulin heavy chain (often IgG1 Fc) with non-light chain components for functional effect. Abatacept is one recombinant therapeutic protein where the fusion involves IgG1 Fc and the extracellular domain of CTLA-4 (CD152), resulting in disruption of antigen presenting cell costimulation of T-cells. Abatacept is used to treat rheumatologic diseases including rheumatoid arthritis. To date, these chimeric proteins have not been described as diagnostic confounders, although the potential exists given the presence of an immunoreactive immunoglobulin heavy chain. Indeed, we observed restrictions anodal to normal gammaglobulins overlapping the alpha 2 region on SIFE (Sebia Hydrasys) in patients receiving intravenous abatacept; these restrictions had gamma specificity but no associated light chain. Based on laboratory evaluation alone, there would be potential concern for possible gamma heavy chain disease. However, neither of our two index patients had symptoms or suspicion of a B-cell neoplasm. Notably, index hypogammaglobulinemic clinical samples were collected at 1 hour and 3 days post-abatacept infusion, respectively, when near-maximal serum concentrations are expected. Abatacept 10 mg/kg intravenous dosing has maximum serum concentration (Cmax) and half-life of approximately 0.2 mg/mL and 14 days, respectively (5). SPEP and immunosubtraction (Sebia Capillarys Flex Piercing 2) were unremarkable. To further evaluate the likelihood the isolated gamma restrictions represented abatacept, sera from our second patient were collected for clinical evaluation 2 days before and 1 day after her monthly infusion. When SIFE was performed at standard dilutions, the sample obtained before infusion no longer clearly showed the IgG restriction; however, the post-infusion sample demonstrated the restriction (Fig. 1). For comparison, when performed without dilution, SIFE showed the IgG-only restriction in both pre- and post-infusion samples but with darker restriction in the post-infusion sample consistent with higher concentration (Fig. 1). Finally, recombinant abatacept (Selleck Chemicals, reconstituted 1 mg/mL) had similar appearance on immunofixation down to at least 0.1 mg/mL (Fig. 1, immunofixation 2, lane “G10”) and when spiked into normal serum yielding Cmax concentration (0.2 mg/mL, Fig. 1). The concentration of gammaglobulins (e.g., hypogammaglobulinemia) and resultant SIFE dilutions may impact the sensitivity of abatacept detection. Serum immunofixation demonstrating presence and appearance of abatacept. Immunofixations 7 and 8 represent pre-infusion samples performed at standard dilutions and neat, respectively; immunofixations 4 and 5 represent post-infusion samples of the same patient at standard dilutions and neat, respectively. The restriction present in the IgG lane alone is more prominent in the post-infusion samples (immunofixations 4 and 5) compared to pre-infusion samples (immunofixations 7 and 8), consistent with increased concentration post-infusion. Recombinant abatacept (neat = 1 mg/mL) is shown on standard immunofixation 1 and with serial dilutions only with anti-IgG (immunofixation 2). A comparison normal serum sample is shown in immunofixation 9, which was then spiked with reconstituted abatacept (1:5, abatacept concentration of 0.2 mg/mL) and shown in immunofixations 6 (standard dilutions) and 3 (neat). Samples are used at dilutions indicated numerically or by “n” to indicate neat. Arrow denotes abatacept restriction. Abbreviations: G, IgG; A, IgA; M, IgM; K, kappa; L, lambda; ELP, electrophoresis lane. We are not aware of prior reports of a chimeric protein mimicking gamma heavy chain disease. A lack of such reporting could be due to chimeric protein pharmacokinetics, routes of administration (e.g., topical ophthalmologic or subcutaneous injection), and unclear rates of therapy in patients being evaluated for paraproteins. For abatacept, while subcutaneous injections are common, intravenous administration is also used in both loading and maintenance dosing depending on clinical indications. This direct infusion likely contributes to detection with SIFE. Although a rare finding, this report highlights the possibility of additional recombinant therapeutics acting as diagnostic mimics outside of classical TmAbs. The importance of patient-specific information, including non-TmAb biologic therapies and paraprotein history, are important to minimize the risk of incorrect results and potentially wasteful evaluations and clinical workups. TmAb, therapeutic monoclonal antibody; SPEP, serum protein electrophoresis; SIFE, serum immunofixation; Cmax, maximum serum concentration. The corresponding author takes full responsibility that all authors on this publication have met the following required criteria of eligibility for authorship: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. Nobody who qualifies for authorship has been omitted from the list. David Manthei (Conceptualization-Equal, Data curation-Equal, Formal analysis-Equal, Investigation-Equal, Methodology-Equal, Resources-Equal, Writing—original draft-Equal, Writing—review & editing-Equal) No authors declared any potential conflicts of interest.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heavy Chain DiseaseAntirheumatic AgentsHumansAbatacept

Substanzen

AbataceptAntirheumatic Agents

Autor:innen und Institutionen

  • Department of Pathology, University of Michigan, Ann Arbor, MI 48109, United States.

Zitieren

APA

Manthei, D. M. (2023). Abatacept as a Mimic of Gamma Heavy Chain Disease. Clinical Chemistry. https://doi.org/10.1093/clinchem/hvad074

Vancouver

Manthei DM. Abatacept as a Mimic of Gamma Heavy Chain Disease. Clinical Chemistry. 2023. doi:10.1093/clinchem/hvad074

BibTeX
@article{Manthei2023,
  author = {Manthei, David M},
  title = {Abatacept as a Mimic of Gamma Heavy Chain Disease},
  journal = {Clinical Chemistry},
  year = {2023},
  doi = {10.1093/clinchem/hvad074}
}
Kostenlos starten →